Endometrial endometrioid adenocarcinoma
diseaseOn this page
Also known as endometrioid adenocarcinoma of endometriumendometrioid adenocarcinoma of the endometriumendometrioid carcinoma of endometriumendometrioid carcinoma of the endometriumendometrioid endomet. adenocar.endometrioid endometrial adenocarcinomauterine corpus endometrioid adenocarcinomauterine corpus endometrioid carcinomauterine endometrioid carcinoma
Summary
Endometrial endometrioid adenocarcinoma (MONDO:0006192) is a disease (an umbrella term covering 5 Mondo subtypes) and 25 clinical trials. Top therapeutic interventions include carboplatin, megestrol acetate, and copanlisib. A subtype of endometrioid adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 25
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | endometrial endometrioid adenocarcinoma |
| Mondo ID | MONDO:0006192 |
| EFO | EFO:1000233 |
| ICD-11 | 671511103 |
| NCIT | C6287 |
| UMLS | C1336905 |
| MedGen | 234467 |
| Is cancer (heuristic) | no |
Also known as: endometrial endometrioid adenocarcinoma · endometrioid adenocarcinoma of endometrium · endometrioid adenocarcinoma of the endometrium · endometrioid carcinoma of endometrium · endometrioid carcinoma of the endometrium · endometrioid endomet. adenocar. · endometrioid endometrial adenocarcinoma · uterine corpus endometrioid adenocarcinoma · uterine corpus endometrioid carcinoma · uterine endometrioid carcinoma
Disease family
This is a subtype of endometrioid adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › endometrioid adenocarcinoma › endometrial endometrioid adenocarcinoma
Related subtypes (5): cervical endometrioid adenocarcinoma, fallopian tube endometrioid adenocarcinoma, stage I endometrioid carcinoma, stage II endometrioid carcinoma, ovarian endometrioid adenocarcinoma
Subtypes (5): villoglandular endometrial endometrioid adenocarcinoma, oxyphilic endometrial endometrioid adenocarcinoma, secretory uterine corpus endometrioid adenocarcinoma, mucin-rich endometrial endometrioid adenocarcinoma, endometrial endometrioid adenocarcinoma with spindled epithelial cells
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 25.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 11 |
| PHASE1 | 5 |
| PHASE3 | 4 |
| Not specified | 3 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03422198 | PHASE3 | RECRUITING | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer |
| NCT03914612 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer |
| NCT04214067 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer |
| NCT05256225 | PHASE3 | RECRUITING | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma |
| NCT03008408 | PHASE2 | ACTIVE_NOT_RECRUITING | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma |
| NCT03348631 | PHASE2 | ACTIVE_NOT_RECRUITING | Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer |
| NCT04719273 | PHASE2 | ACTIVE_NOT_RECRUITING | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer |
| NCT05112601 | PHASE2 | RECRUITING | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma |
| NCT05538897 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers |
| NCT06278857 | PHASE2 | RECRUITING | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) |
| NCT07107334 | PHASE2 | RECRUITING | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia |
| NCT07436793 | PHASE2 | NOT_YET_RECRUITING | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial |
| NCT00478426 | PHASE2 | COMPLETED | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
| NCT00492778 | PHASE2 | UNKNOWN | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer |
| NCT02684227 | PHASE2 | COMPLETED | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer |
| NCT02728258 | PHASE2 | COMPLETED | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer |
| NCT03120624 | PHASE1 | ACTIVE_NOT_RECRUITING | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer |
| NCT05542407 | PHASE1 | RECRUITING | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer |
| NCT05950464 | PHASE1 | RECRUITING | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer |
| NCT02020707 | PHASE1 | COMPLETED | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers |
| NCT05498597 | PHASE1 | UNKNOWN | AMT-151 in Patients With Selected Advanced Solid Tumours |
| NCT04049227 | EARLY_PHASE1 | COMPLETED | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer |
| NCT03677024 | Not specified | WITHDRAWN | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas |
| NCT04972682 | Not specified | COMPLETED | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer |
| NCT07226102 | Not specified | WITHDRAWN | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CARBOPLATIN | 4 | 3 |
| MEGESTROL ACETATE | 4 | 2 |
| COPANLISIB | 4 | 1 |
| DOSTARLIMAB | 4 | 1 |
| HYALURONIDASE (HUMAN RECOMBINANT) | 4 | 1 |
| PEMBROLIZUMAB | 4 | 1 |
| PERTUZUMAB | 4 | 1 |
| RIBOCICLIB | 4 | 1 |
| RUXOLITINIB | 4 | 1 |
| SODIUM PERTECHNETATE TC 99M | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| TAZEMETOSTAT | 4 | 1 |
| DORDAVIPRONE | 3 | 1 |
| IPATASERTIB | 3 | 1 |
| ONAPRISTONE | 2 | 1 |
| TUVUSERTIB | 2 | 1 |
| ZEN-3694 | 2 | 1 |
| ZENIDOLOL | 2 | 1 |
| CHEMBL4567541 | 0 | 2 |
| CHEMBL3109278 | 0 | 1 |
| CHEMBL5398431 | 0 | 1 |